Cargando…

Preliminary Results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the Treatment of Benign Bone Tumors and Tumor-like Lesions

Background: CERAMENT™|BONE VOID FILLER is an injectable and moldable ceramic bone substitute material intended for bone voids. The material consists of hydroxyapatite and calcium sulfate hemihydrate. The aim of this study is to present the first long-term results following open curettage of benign b...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotrych, Daniel, Korecki, Szymon, Ziętek, Paweł, Kruk, Bartosz, Kruk, Agnieszka, Wechmann, Michał, Kamiński, Adam, Kotrych, Katarzyna, Bohatyrewicz, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6227780/
https://www.ncbi.nlm.nih.gov/pubmed/30426086
http://dx.doi.org/10.1515/med-2018-0072
_version_ 1783369997498712064
author Kotrych, Daniel
Korecki, Szymon
Ziętek, Paweł
Kruk, Bartosz
Kruk, Agnieszka
Wechmann, Michał
Kamiński, Adam
Kotrych, Katarzyna
Bohatyrewicz, Andrzej
author_facet Kotrych, Daniel
Korecki, Szymon
Ziętek, Paweł
Kruk, Bartosz
Kruk, Agnieszka
Wechmann, Michał
Kamiński, Adam
Kotrych, Katarzyna
Bohatyrewicz, Andrzej
author_sort Kotrych, Daniel
collection PubMed
description Background: CERAMENT™|BONE VOID FILLER is an injectable and moldable ceramic bone substitute material intended for bone voids. The material consists of hydroxyapatite and calcium sulfate hemihydrate. The aim of this study is to present the first long-term results following open curettage of benign bone tumors and tumor-like lesions and void filling with this novel injectable and synthetic bone graft. Methods: Thirty three patients were enrolled into the study between June 2013 and October 2014 .Totally, we treated 24 women and 9 men with a median age of 47 years (range: 22-74). All patients suffered from primary musculoskeletal system disorders (enchondroma 63,6%, giant cell tumor 18%, aneurysmal bone cyst 9%, fibrous dysplasia 9%, Gaucher disease 3%). We performed curettage of pathological lesions, then the bone substitute was administered by means of needle to the void. Results: The average follow-up was 13 months (range: 2-13 months, median 10 months). No metastasis or recurrence had been detected. We received significant clinical improvement relating to VAS, MSTS, and oncological results. Conclusions: The results of our study report that CERAMENT can be successfully used as a bone substitute in patients with various bone diseases, as well as benign bone tumors. CERAMENT can provide an effective and long-term solution for reconstructive procedures following curettage of bone tumors and tumor like lesions.
format Online
Article
Text
id pubmed-6227780
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-62277802018-11-13 Preliminary Results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the Treatment of Benign Bone Tumors and Tumor-like Lesions Kotrych, Daniel Korecki, Szymon Ziętek, Paweł Kruk, Bartosz Kruk, Agnieszka Wechmann, Michał Kamiński, Adam Kotrych, Katarzyna Bohatyrewicz, Andrzej Open Med (Wars) Regular Articles Background: CERAMENT™|BONE VOID FILLER is an injectable and moldable ceramic bone substitute material intended for bone voids. The material consists of hydroxyapatite and calcium sulfate hemihydrate. The aim of this study is to present the first long-term results following open curettage of benign bone tumors and tumor-like lesions and void filling with this novel injectable and synthetic bone graft. Methods: Thirty three patients were enrolled into the study between June 2013 and October 2014 .Totally, we treated 24 women and 9 men with a median age of 47 years (range: 22-74). All patients suffered from primary musculoskeletal system disorders (enchondroma 63,6%, giant cell tumor 18%, aneurysmal bone cyst 9%, fibrous dysplasia 9%, Gaucher disease 3%). We performed curettage of pathological lesions, then the bone substitute was administered by means of needle to the void. Results: The average follow-up was 13 months (range: 2-13 months, median 10 months). No metastasis or recurrence had been detected. We received significant clinical improvement relating to VAS, MSTS, and oncological results. Conclusions: The results of our study report that CERAMENT can be successfully used as a bone substitute in patients with various bone diseases, as well as benign bone tumors. CERAMENT can provide an effective and long-term solution for reconstructive procedures following curettage of bone tumors and tumor like lesions. De Gruyter 2018-10-22 /pmc/articles/PMC6227780/ /pubmed/30426086 http://dx.doi.org/10.1515/med-2018-0072 Text en © 2018 Daniel Kotrych et al., published by De Gruyter http://creativecommons.org/licenses/by-nc-nd/4.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
spellingShingle Regular Articles
Kotrych, Daniel
Korecki, Szymon
Ziętek, Paweł
Kruk, Bartosz
Kruk, Agnieszka
Wechmann, Michał
Kamiński, Adam
Kotrych, Katarzyna
Bohatyrewicz, Andrzej
Preliminary Results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the Treatment of Benign Bone Tumors and Tumor-like Lesions
title Preliminary Results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the Treatment of Benign Bone Tumors and Tumor-like Lesions
title_full Preliminary Results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the Treatment of Benign Bone Tumors and Tumor-like Lesions
title_fullStr Preliminary Results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the Treatment of Benign Bone Tumors and Tumor-like Lesions
title_full_unstemmed Preliminary Results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the Treatment of Benign Bone Tumors and Tumor-like Lesions
title_short Preliminary Results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the Treatment of Benign Bone Tumors and Tumor-like Lesions
title_sort preliminary results of highly injectable bi-phasic bone substitute (cerament) in the treatment of benign bone tumors and tumor-like lesions
topic Regular Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6227780/
https://www.ncbi.nlm.nih.gov/pubmed/30426086
http://dx.doi.org/10.1515/med-2018-0072
work_keys_str_mv AT kotrychdaniel preliminaryresultsofhighlyinjectablebiphasicbonesubstituteceramentinthetreatmentofbenignbonetumorsandtumorlikelesions
AT koreckiszymon preliminaryresultsofhighlyinjectablebiphasicbonesubstituteceramentinthetreatmentofbenignbonetumorsandtumorlikelesions
AT zietekpaweł preliminaryresultsofhighlyinjectablebiphasicbonesubstituteceramentinthetreatmentofbenignbonetumorsandtumorlikelesions
AT krukbartosz preliminaryresultsofhighlyinjectablebiphasicbonesubstituteceramentinthetreatmentofbenignbonetumorsandtumorlikelesions
AT krukagnieszka preliminaryresultsofhighlyinjectablebiphasicbonesubstituteceramentinthetreatmentofbenignbonetumorsandtumorlikelesions
AT wechmannmichał preliminaryresultsofhighlyinjectablebiphasicbonesubstituteceramentinthetreatmentofbenignbonetumorsandtumorlikelesions
AT kaminskiadam preliminaryresultsofhighlyinjectablebiphasicbonesubstituteceramentinthetreatmentofbenignbonetumorsandtumorlikelesions
AT kotrychkatarzyna preliminaryresultsofhighlyinjectablebiphasicbonesubstituteceramentinthetreatmentofbenignbonetumorsandtumorlikelesions
AT bohatyrewiczandrzej preliminaryresultsofhighlyinjectablebiphasicbonesubstituteceramentinthetreatmentofbenignbonetumorsandtumorlikelesions